

Ghada El-Hajj Fuleihan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3389920/publications.pdf>

Version: 2024-02-01

132
papers

9,008
citations

53939

47
h-index

48101

92
g-index

135
all docs

135
docs citations

135
times ranked

9288
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamin D Supplementation and Fractures in Adults: A Systematic Umbrella Review of Meta-Analyses of Controlled Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 882-898.	1.8	35
2	Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials. <i>Metabolism: Clinical and Experimental</i> , 2022, 128, 154962.	1.5	6
3	Effect of high dose vitamin D supplementation on indices of sarcopenia and obesity assessed by DXA among older adults: A randomized controlled trial. <i>Endocrine</i> , 2022, , 1.	1.1	12
4	Reply to Editorsâ€™Effect of high dose vitamin D supplementation on indices of sarcopenia and obesity assessed by DXA among older adults: a randomized controlled trial. <i>Endocrine</i> , 2022, , 1.	1.1	1
5	Enhancing the Trustworthiness of the Endocrine Societyâ€™s Clinical Practice Guidelines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2129-2138.	1.8	5
6	Total, Bioavailable, and Free 25(OH)D Relationship with Indices of Bone Health in Elderly: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e990-e1001.	1.8	13
7	Osteoporotic hip and vertebral fractures in the Arab region: a systematic review. <i>Osteoporosis International</i> , 2021, 32, 1499-1515.	1.3	6
8	Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3644-e3654.	1.8	7
9	The link between COVID-19 and Vitamin D (VIVID): A systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2021, 119, 154753.	1.5	142
10	Values and other decisional factors regarding treatment of hypercalcaemia of malignancy: a systematic review protocol. <i>BMJ Open</i> , 2021, 11, e051141.	0.8	3
11	Treatment of Hypercalcemia of Malignancy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 781-792.	1.2	7
12	Management of Hip Fractures at an Academic Center: Challenges and Opportunities. <i>Journal of Clinical Densitometry</i> , 2020, 23, 524-533.	0.5	5
13	Impact of vitamin D supplementation on falls and fracturesâ€™A critical appraisal of the quality of the evidence and an overview of the available guidelines. <i>Bone</i> , 2020, 131, 115112.	1.4	20
14	Secular Trends of Hip Fractures in Lebanon, 2006 to 2017: Implications for Clinical Practice and Public Health Policy in the Middle East Region. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 71-80.	3.1	12
15	Time trends and predictors of hypovitaminosis D across the life course: 2009â€™2016. <i>Metabolism: Clinical and Experimental</i> , 2020, 105, 154138.	1.5	17
16	Building Bridges to Address the Osteoporosis Crisis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1292-1293.	1.8	2
17	Disease burden of osteoporosis and other non-communicable diseases in Lebanon. <i>Osteoporosis International</i> , 2020, 31, 1769-1777.	1.3	3
18	Delta-like 1 (DLK1) is a possible mediator of vitamin D effects on bone and energy metabolism. <i>Bone</i> , 2020, 138, 115510.	1.4	2

#	ARTICLE	IF	CITATIONS
19	The D-side of COVID-19: musculoskeletal benefits of vitamin D and beyond. <i>Endocrine</i> , 2020, 69, 237-240.	1.1	38
20	Systematic review of major osteoporotic fracture to hip fracture incidence rate ratios worldwide: implications for Fracture Risk Assessment Tool (FRAX)-derived estimates. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1942-1956.	3.1	15
21	Rate of drop in serum calcium as a predictor of hypocalcemic symptoms post total thyroidectomy. <i>Osteoporosis International</i> , 2019, 30, 2495-2504.	1.3	5
22	Management of osteoporosis in the Middle East and North Africa: a survey of physicians' perceptions and practices. <i>Archives of Osteoporosis</i> , 2019, 14, 60.	1.0	8
23	Vitamin D supplementation in obesity and during weight loss: A review of randomized controlled trials. <i>Metabolism: Clinical and Experimental</i> , 2019, 92, 193-205.	1.5	54
24	Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. <i>European Journal of Endocrinology</i> , 2019, 180, P23-P54.	1.9	443
25	Does vitamin D supplementation improve bone density in vitamin D-deficient children? Protocol for an individual patient data meta-analysis. <i>BMJ Open</i> , 2018, 8, e019584.	0.8	5
26	Vitamin D in the Middle East and North Africa. <i>Bone Reports</i> , 2018, 8, 135-146.	0.2	87
27	Limitations of platform assays to measure serum 25OHD level impact on guidelines and practice decision making. <i>Metabolism: Clinical and Experimental</i> , 2018, 89, 1-7.	1.5	13
28	Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature. <i>Osteoporosis International</i> , 2018, 29, 1987-2009.	1.3	14
29	Vitamin D replacement in children, adolescents and pregnant women in the Middle East and North Africa. <i>Metabolism: Clinical and Experimental</i> , 2017, 70, 160-176.	1.5	21
30	Impact of Calcium and Two Doses of Vitamin D on Bone Metabolism in the Elderly: A Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1486-1495.	3.1	31
31	Worldwide prevalence and incidence of osteoporotic vertebral fractures. <i>Osteoporosis International</i> , 2017, 28, 1531-1542.	1.3	301
32	Vitamin D Metabolism in Bariatric Surgery. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017, 46, 947-982.	1.2	25
33	Worldwide Fracture Prediction. <i>Journal of Clinical Densitometry</i> , 2017, 20, 397-424.	0.5	60
34	CYP2R1 polymorphisms are important modulators of circulating 25-hydroxyvitamin D levels in elderly females with vitamin insufficiency, but not of the response to vitamin D supplementation. <i>Osteoporosis International</i> , 2017, 28, 279-290.	1.3	27
35	Persistent Effect of Vitamin D Supplementation on Musculoskeletal Parameters in Adolescents One Year After Trial Completion. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1473-1480.	3.1	9
36	Predictors of trabecular bone score in school children. <i>Osteoporosis International</i> , 2016, 27, 703-710.	1.3	33

#	ARTICLE	IF	CITATIONS
37	The Relationship Between Calcitropic Hormones, IGF-1, and Bone Mass Across Pubertal Stages. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4860-4870.	1.8	14
38	Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 16-35.	3.1	491
39	Effect of vitamin D replacement on indexes of insulin resistance in overweight elderly individuals: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 315-323.	2.2	38
40	Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1119-1133.	3.1	138
41	Effects of hormone therapy on blood pressure. <i>Menopause</i> , 2015, 22, 456-468.	0.8	28
42	Geographic and ethnic disparities in osteoporotic fractures. <i>Nature Reviews Endocrinology</i> , 2014, 10, 338-351.	4.3	256
43	Secular Trends in Hip Fractures Worldwide: Opposing Trends East Versus West. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1745-1755.	3.1	145
44	Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass. <i>Osteoporosis International</i> , 2014, 25, 423-439.	1.3	70
45	Dual-Energy X-Ray Absorptiometry Interpretation and Reporting in Children and Adolescents: The Revised 2013 ISCD Pediatric Official Positions. <i>Journal of Clinical Densitometry</i> , 2014, 17, 225-242.	0.5	444
46	Vitamin D in endometriosis: A causative or confounding factor?. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 32-41.	1.5	34
47	Association between low vitamin D levels and the diagnosis of asthma in children: a systematic review of cohort studies. <i>Allergy, Asthma and Clinical Immunology</i> , 2014, 10, 31.	0.9	20
48	Hypovitaminosis D in a sunny country: Time trends, predictors, and implications for practice guidelines. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 968-978.	1.5	47
49	Impact of changes in mortality on FRAX-derived fracture probabilities. <i>Bone</i> , 2014, 62, 43-50.	1.4	7
50	Vitamin D3 Dose Requirement to Raise 25-Hydroxyvitamin D to Desirable Levels in Adolescents: Results from a Randomized Controlled Trial. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 944-951.	3.1	29
51	Estrogen receptor β is not a candidate gene for metabolic syndrome in Caucasian elderly subjects. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 50-60.	1.5	3
52	Effect of vitamin D replacement on hip structural geometry in adolescents: A randomized controlled trial. <i>Bone</i> , 2013, 56, 296-303.	1.4	31
53	Gender Differences in the Heritability of Musculoskeletal and Body Composition Parameters in Mother-Daughter and Mother-Son Pairs. <i>Journal of Clinical Densitometry</i> , 2013, 16, 223-230.	0.5	6
54	Geographic Variability in Hip and Vertebral Fractures. , 2013, , 623-644.		8

#	ARTICLE	IF	CITATIONS
55	Hypovitaminosis D in the Middle East and North Africa. <i>Dermato-Endocrinology</i> , 2013, 5, 274-298.	1.9	148
56	Do Desirable Vitamin D Levels Vary Globally?. , 2013, , 273-299.		8
57	Use of recombinant human parathyroid hormone in hypocalcemic cardiomyopathy. <i>European Journal of Endocrinology</i> , 2012, 166, 1113-1120.	1.9	27
58	25-Hydroxyvitamin D Assay Variations and Impact on Clinical Decision Making. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 835-843.	1.8	70
59	Parathyromatosis: a rare yet problematic etiology of recurrent and persistent hyperparathyroidism. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 762-775.	1.5	40
60	Can the sunshine vitamin melt the fat?. <i>Metabolism: Clinical and Experimental</i> , 2012, 61, 603-610.	1.5	12
61	Predictors of bone loss in childhood hematologic malignancies: a prospective study. <i>Osteoporosis International</i> , 2012, 23, 665-674.	1.3	17
62	FRAAX® International Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. <i>Journal of Clinical Densitometry</i> , 2011, 14, 237-239.	0.5	19
63	Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAAX®. <i>Journal of Clinical Densitometry</i> , 2011, 14, 171-180.	0.5	82
64	Official Positions for FRAAX® Clinical Regarding International Differences. <i>Journal of Clinical Densitometry</i> , 2011, 14, 240-262.	0.5	84
65	Hip fracture incidence in Lebanon: a national registry-based study with reference to standardized rates worldwide. <i>Osteoporosis International</i> , 2011, 22, 2499-2506.	1.3	33
66	Hypovitaminosis D in developing countriesâ€™ prevalence, risk factors and outcomes. <i>Nature Reviews Endocrinology</i> , 2010, 6, 550-561.	4.3	268
67	Age but not gender modulates the relationship between PTH and vitamin D. <i>Bone</i> , 2010, 47, 408-412.	1.4	50
68	Vitamin D Deficiency in the Middle East and Its Health Consequences. , 2010, , 469-494.		5
69	Endocrine and musculoskeletal abnormalities in patients with Down syndrome. <i>Nature Reviews Endocrinology</i> , 2009, 5, 327-334.	4.3	80
70	Vitamin D Deficiency in the Middle East and its Health Consequences for Children and Adults. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2009, 7, 77-93.	1.3	59
71	Vitamin D receptor gene polymorphisms modulate the skeletal response to vitamin D supplementation in healthy girls. <i>Bone</i> , 2009, 45, 1091-1097.	1.4	45
72	Modeling Pathways for Low Bone Mass in Children With Malignancies. <i>Journal of Clinical Densitometry</i> , 2009, 12, 441-449.	0.5	10

#	ARTICLE	IF	CITATIONS
73	Risk Estimates for Hip Fracture From Clinical and Densitometric Variables and Impact of Database Selection in Lebanese Subjects. <i>Journal of Clinical Densitometry</i> , 2009, 12, 272-278.	0.5	3
74	Impact of maternal veiling during pregnancy and socioeconomic status on offspring's musculoskeletal health. <i>Osteoporosis International</i> , 2008, 19, 295-302.	1.3	20
75	Vitamin D: A Growing Perspective. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2008, 45, 339-414.	2.7	112
76	Predictors of bone density in ambulatory patients on antiepileptic drugs. <i>Bone</i> , 2008, 43, 149-155.	1.4	104
77	Dual Energy X-ray Absorptiometry Interpretation and Reporting in Children and Adolescents: The 2007 ISCD Pediatric Official Positions. <i>Journal of Clinical Densitometry</i> , 2008, 11, 43-58.	0.5	480
78	First Update of the Lebanese Guidelines for Osteoporosis Assessment and Treatment. <i>Journal of Clinical Densitometry</i> , 2008, 11, 383-396.	0.5	10
79	Tibolone and the Promise of Ideal Hormone-Replacement Therapy. <i>New England Journal of Medicine</i> , 2008, 359, 753-755.	13.9	14
80	How effective is risedronate in preventing bone loss in patients on high-dose steroids?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 540-541.	2.9	1
81	Hyperparathyroidism: Time to Reconsider Current Clinical Decision Paradigms?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3302-3304.	1.8	9
82	Short- and Long-Term Safety of Weekly High-Dose Vitamin D3 Supplementation in School Children. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2693-2701.	1.8	125
83	Hypercalcemia and diabetes insipidus in a patient previously treated with lithium. <i>Nature Clinical Practice Nephrology</i> , 2007, 3, 397-404.	2.0	38
84	Vertebral fracture risk and impact of database selection on identifying elderly Lebanese with osteoporosis. <i>Bone</i> , 2007, 40, 1066-1072.	1.4	33
85	Discriminative ability of dual-energy X-ray absorptiometry site selection in identifying patients with osteoporotic fractures. <i>Bone</i> , 2007, 40, 1060-1065.	1.4	47
86	Vitamin D insufficiency and musculoskeletal health in children and adolescents. <i>International Congress Series</i> , 2007, 1297, 91-108.	0.2	24
87	First update of the Lebanese guidelines for osteoporosis assessment and treatment. <i>Journal Medical Libanais</i> , 2007, 55, 176-91.	0.0	6
88	Calcium and Bone Disorders During Pregnancy and Lactation. <i>Endocrinology and Metabolism Clinics of North America</i> , 2006, 35, 21-51.	1.2	115
89	Application of the 1994 WHO Classification to Populations Other Than Postmenopausal Caucasian Women: The 2005 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , 2006, 9, 22-30.	0.5	116
90	Dermatologic manifestations of parathyroid-related disorders. <i>Clinics in Dermatology</i> , 2006, 24, 281-288.	0.8	34

#	ARTICLE	IF	CITATIONS
91	Hypovitaminosis D osteopathy: Is it mediated through PTH, lean mass, or is it a direct effect?. Bone, 2006, 39, 268-275.	1.4	50
92	An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines. Osteoporosis International, 2006, 17, 1111-1115.	1.3	14
93	Effect of Vitamin D Replacement on Musculoskeletal Parameters in School Children: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 405-412.	1.8	337
94	Regression of Skeletal Manifestations of Hyperparathyroidism with Oral Vitamin D. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2480-2483.	1.8	22
95	High Plasma Leptin Is Not Associated with Higher Bone Mineral Density in Insulin-Resistant Premenopausal Obese Women. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2588-2594.	1.8	21
96	Lebanese Guidelines for Osteoporosis Assessment and Treatment. Journal of Clinical Densitometry, 2005, 8, 148-163.	0.5	7
97	Impact of anthropometric, lifestyle, and body composition variables on ultrasound measurements in school children. Bone, 2005, 36, 736-742.	1.4	40
98	Densitometer Type and Impact on Risk Assessment for Osteoporosis. Journal of Clinical Densitometry, 2005, 8, 261-266.	0.5	1
99	Pamidronate in the Prevention of Chemotherapy-Induced Bone Loss in Premenopausal Women with Breast Cancer: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3209-3214.	1.8	91
100	Sex differences in the effect of body-composition variables on bone mass in healthy children and adolescents. American Journal of Clinical Nutrition, 2004, 80, 1428-1435.	2.2	79
101	Strontium Ranelate "A Novel Therapy for Osteoporosis or a Permutation of the Same?. New England Journal of Medicine, 2004, 350, 504-506.	13.9	31
102	Safety and Efficacy of Risedronate in Reducing Fracture Risk in Osteoporotic Women Aged 80 and Older: Implications for the Use of Antiresorptive Agents in the Old and Oldest Old. Journal of the American Geriatrics Society, 2004, 52, 1832-1839.	1.3	167
103	Hip Fractures in Lebanese Patients. Journal of Clinical Densitometry, 2004, 7, 368-375.	0.5	13
104	Bone mineral density by age, gender, pubertal stages, and socioeconomic status in healthy Lebanese children and adolescents. Bone, 2004, 35, 1169-1179.	1.4	115
105	Predictors of bone mineral density in patients on hemodialysis. Transplantation Proceedings, 2004, 36, 1297-1301.	0.3	28
106	Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas, 2004, 48, 243-251.	1.0	96
107	Effect of gender, puberty, and vitamin D status on biochemical markers of bone remodeling. Bone, 2003, 33, 242-247.	1.4	67
108	Summary Statement from a Workshop on Asymptomatic Primary Hyperparathyroidism: A Perspective for the 21st Century. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5353-5361.	1.8	577

#	ARTICLE	IF	CITATIONS
109	Efficacy and Tolerability of Cyclical Intravenous Pamidronate in Patients with Low Bone Mass. Journal of Clinical Densitometry, 2002, 5, 143-149.	0.5	17
110	Hypercalcemia in langerhansâ€™ cell granulomatosis with elevated 1,25 dihydroxyvitamin D (calcitriol) level. Bone, 2002, 30, 331-334.	1.4	21
111	Low peak bone mineral density in healthy lebanese subjects. Bone, 2002, 31, 520-528.	1.4	54
112	A National Random Survey of Bone Mineral Density Reporting in the United States. Journal of Clinical Densitometry, 2002, 5, 3-9.	0.5	13
113	Familial Benign Hypocalciuric Hypercalcemia and Neonatal Hyperparathyroidism. Clinical Reviews in Bone and Mineral Metabolism, 2002, 1, 77-84.	1.3	2
114	Familial benign hypocalciuric hypercalcemia. Journal of Bone and Mineral Research, 2002, 17 Suppl 2, N51-6.	3.1	9
115	Practice guidelines on the use of bone mineral density measurements: Who to test? What measures to use? When to treat? A consensus report from the Middle East Densitometry Workshop. Journal Medical Libanais, 2002, 50, 89-104.	0.0	3
116	Hypovitaminosis D in Healthy Schoolchildren. Pediatrics, 2001, 107, e53-e53.	1.0	299
117	The effects of age and gender on parathyroid hormone dynamics. Clinical Endocrinology, 2000, 52, 329-338.	1.2	74
118	Hypovitaminosis D in a Sunny Country. New England Journal of Medicine, 1999, 340, 1840-1841.	13.9	83
119	Longitudinal Changes in Bone Density in Hyperparathyroidism. Journal of Clinical Densitometry, 1999, 2, 153-162.	0.5	23
120	Calcium modulation of the renin-aldosterone axis. Journal of Endocrinological Investigation, 1999, 22, 115-121.	1.8	11
121	Osteoporosis: an overview of practice guidelines for bone density measurements and osteoporosis treatment strategies. Journal Medical Libanais, 1999, 47, 222-8.	0.0	0
122	Calcium-Regulated Renal Calcium Handling in Healthy Men: Relationship to Sodium Handling ¹ . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2366-2372.	1.8	60
123	Tissue-Specific Estrogens â€™ The Promise for the Future. New England Journal of Medicine, 1997, 337, 1686-1687.	13.9	24
124	The Parathyroid Hormone Circadian Rhythm Is Truly Endogenousâ€™A General Clinical Research Center Study¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 281-286.	1.8	121
125	Modeling Fracture Risk Using Bone Density, Age, and Years Since Menopause. American Journal of Preventive Medicine, 1997, 13, 447-452.	1.6	8
126	Reproducibility of DXA absorptiometry: A model for bone loss estimates. Journal of Bone and Mineral Research, 1995, 10, 1004-1014.	3.1	96

#	ARTICLE	IF	CITATIONS
127	Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 1713-1718.	3.1	69
128	Hypervitaminosis D Associated with Drinking Milk. <i>New England Journal of Medicine</i> , 1992, 326, 1173-1177.	13.9	248
129	The gene responsible for familial hypocalciuric hypercalcemia maps to chromosome 3q in four unrelated families. <i>Nature Genetics</i> , 1992, 1, 295-300.	9.4	152
130	Dual-energy X-ray absorptiometry of the forearm: Reproducibility and correlation with single-photon absorptiometry. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 841-846.	3.1	37
131	A Comparison of the Effects of Divalent and Trivalent Cations on Parathyroid Hormone Release, 3 α ,5 β -Cyclic-Adenosine Monophosphate Accumulation, and the Levels of Inositol Phosphates in Bovine Parathyroid Cells. <i>Endocrinology</i> , 1990, 127, 1064-1071.	1.4	95
132	Calcium-Dependent Release of N-Terminal Fragments and Intact Immunoreactive Parathyroid Hormone by Human Pathological Parathyroid Tissue <i>in vitro</i> *. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989, 69, 860-867.	1.8	23